Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

October 9th 2024

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

October 9th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail the 11-0 ODAC vote that new trial designs for perioperative regimens in resectable NSCLC should include within-trial assessment of each treatment phase's contribution.

Dr Garassino on the Potential Use of a TROP2 Biomarker to Predict Outcomes With Dato-DXd in NSCLC

October 8th 2024

Marina Chiara Garassino, MD, discusses the predictive utility of a TROP2 computational pathway biomarker for outcomes with Dato-DXd in pretreated NSCLC.

Dr Girard on the Safety of Nivolumab/Relatlimab/Chemotherapy in Untreated NSCLC

October 8th 2024

Nicolas Girard, MD, discusses the safety of nivolumab plus relatlimab and chemotherapy for untreated stage IV or recurrent non–small cell lung cancer.

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

October 7th 2024

Martin Dietrich, MD, PhD, discusses updated efficacy findings from the 18-month follow-up of the phase 2 VISION trial.

Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC

October 7th 2024

Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.

Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS

October 7th 2024

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

October 6th 2024

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC

October 4th 2024

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC

October 4th 2024

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

Tarlatamab and Durvalumab Enhance the SCLC Immunotherapy Paradigm

October 4th 2024

Isabel Preeshagul, DO, MBS, discusses frontline treatment selection for patients with SCLC and significant FDA approvals in this disease.

FDA Approves Perioperative Nivolumab for Resectable NSCLC

October 3rd 2024

The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC.

Dr Girard on PROs From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

October 3rd 2024

Nicolas Girard, MD, discusses PROs from the LUMINOSITY trial of Teliso-V in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous NSCLC.

Allogeneic T-Cell Therapy Produces Efficacy at 10 Months in Stage IV Metastatic NSCLC

October 1st 2024

Treatment with Deltacel was safe and showed antitumor activity at 10 months in a patient with stage IV metastatic non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week 9/22

September 28th 2024

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.

Dr Gadgeel on Longer-Term Data for Amivantamab Plus Lazertinib in EGFR+ NSCLC

September 27th 2024

Shirish M. Gadgeel, MD, on long-term follow-up data from MARIPOSA for amivantamab plus lazertinib in first-line EGFR-mutated non–small cell lung cancer.

Dr Sands on Consolidation Durvalumab as a Potential New SOC for LS-SCLC After Chemoradiation

September 27th 2024

Jacob Sands, MD, discusses consolidation therapy durvalumab as a new standard of care in limited-stage small cell lung cancer.

Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need

September 27th 2024

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.